(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2009 (11.06.2009)

PCT

(10) International Publication Number
WO 2009/073300 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 11/06* (2006.01)
A61K 31/437 (2006.01) *A61P 17/06* (2006.01)
A61P 29/00 (2006.01) *A61P 19/02* (2006.01)
A61P 35/00 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/US2008/081933

(22) International Filing Date: 31 October 2008 (31.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/984,875	2 November 2007 (02.11.2007)	US
61/044,575	14 April 2008 (14.04.2008)	US
61/100,808	29 September 2008 (29.09.2008)	US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JIMENEZ, Juan-Miguel** [ES/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **MORTIMORE, Michael** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **COLLIER, Philip** [IE/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **MILLER, Andrew** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **YOUNG, Stephen** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **MAK, Chau** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAVIS, Christopher** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **TWIN, Heather** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **BRENCHLEY, Guy** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **BOYALL, Dean** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **SHAZIA, Keily** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 RY (GB). **LUCA, Settimo** [IT/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).


(74) Agent: **KELLY, Susan, C.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA



(I) (IA)

(57) Abstract: The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R_1, R_2, R_3, R_4, R_5, R_6, R_7, x and y are as described herein.

WO 2009/073300 A1

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*